Search

everythinglearnresearchcommunity

for

Search:↓

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

The conversation discusses hair loss treatments, specifically Brassica oleracea extract, glucosinolates, and sulforaphane, and their potential to promote hair growth. Users also mention minoxidil and finasteride as existing treatments.

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

The user is 10 days post-hair transplant, pleased with the results so far, and hopes for increased density. The procedure was done at Vanity Hospital in Istanbul, with around 3400-3750 grafts used.

Hair loss treatments like Minoxidil, finasteride, and stem cell therapies exist, but a complete cure is hindered by genetic complexity and market dynamics. Cloning hair follicles is considered a potential solution, but it's currently not feasible.

The user is experiencing increased hair miniaturization despite using oral minoxidil, dutasteride, and microneedling. They are considering reintroducing finasteride and adjusting dutasteride dosage.

The user has experienced significant hair regrowth using finasteride for 7 months and minoxidil for 3.5 months, with many commenters noting visible progress. The user has not experienced side effects and is considering additional treatments like microneedling.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.

The user experienced positive hair regrowth using topical minoxidil, along with other factors like shorter hair, castor oil, and hair masks. The user is optimistic about further progress and wants to avoid baldness.

The user switched from finasteride to dutasteride after experiencing significant hair shedding and thinning. Recently, they noticed their hair appearing thicker and their hairline improving, questioning if the switch was necessary and if the improvement is due to growth or regrowth.

The patch behind the ear is likely traction alopecia caused by glasses. No specific treatments like Minoxidil, finasteride, or RU58841 were mentioned.

User has been using minoxidil 6%, finasteride 0.3%, tretinoin 0.025%, and microneedling twice a week for 2.5 months. They are considering switching to oral treatments.

The user experienced increased hair density and thickness after 3-4 months using finasteride, minoxidil, dermastamping, ketoconazole, and biotin. They apply minoxidil right after dermastamping without any side effects or shedding.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

The user has been using HIMS chewable for two months to address lifelong thin hair. They are considering a hair transplant as a potential solution.

The user is currently using oral finasteride for hair loss and considering adding Eucapil, dutasteride mesotherapy, and microneedling to their treatment regimen. They are seeking alternatives to minoxidil, such as Stemoxydine, due to concerns about minoxidil's side effects.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

The conversation is about a user experiencing positive hair regrowth results using 1mg of dutasteride, 10% minoxidil, and occasional microneedling, after unsatisfactory results with finasteride. Other users express interest in switching to dutasteride and share similar sentiments about finasteride.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

The conversation is about a person experiencing significant hair loss in the donor area after a hair transplant, with others suggesting it might be shock loss. The person is taking oral minoxidil and dutasteride to help with the issue.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The conversation is about a 24-year-old using microneedling and essential oils, specifically neo hair lotion, to promote hair growth on the temples. The user reports seeing hair growth without using medications, using a 0.5 mm needle roller and planning to switch to a 1.0 mm needle.

Exosomes from Musely are being discussed as a topical hair loss treatment containing ingredients like latanoprost, caffeine, cetirizine, melatonin, vitamin D3, vitamin E, and biotin. Users are curious about its effectiveness and potential side effects, noting it may take 4-6 months to see results.

User asks where to purchase exosomes/AAPE for microneedling hair loss treatment. Links to research on hair regeneration therapy, stem cell therapy, exosome therapy, and dermal exosomes provided.

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

A 23-year-old with high estrogen levels is considering starting finasteride for hair loss and plans to use a low dose topical treatment while also seeking to lower estrogen levels. They will consult an endocrinologist for further guidance.

A user shared their 2-month progress on finasteride 1mg daily and weekly derma rolling, showing noticeable hair regrowth. Replies confirm visible improvement, though some attribute it partially to lighting.

The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.